EU/3/15/1548

About

On 9 October 2015, orphan designation (EU/3/15/1548) was granted by the European Commission to MicroPharm Limited, United Kingdom, for ovine specific immunoglobulin (Fab) fragments raised against Vipera berus venom for the treatment of snakebite envenomation.

The sponsorship was transferred to Diamond Roc EOOD, Bulgaria, in May 2019.

The sponsorship was transferred to Diamond Pharma Services Ireland Limited in February 2020.

Key facts

Active substance
Ovine specific immunoglobulin (Fab) fragments raised against Vipera berus veno
Disease / condition
Treatment of snakebite envenomation
Date of first decision
09/10/2015
Outcome
Positive
EU designation number
EU/3/15/1548

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Diamond Pharma Services Ireland Limited 
Coliemore House
Coliemore Road
Dalkey
Co. Dublin
Ireland 
Tel. 02039119410
E-mail: mgraham@diamondpharmaservices.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating